195 related articles for article (PubMed ID: 24349631)
1. Mixed Lineage Kinase-c-Jun N-Terminal Kinase Axis: A Potential Therapeutic Target in Cancer.
Rana A; Rana B; Mishra R; Sondarva G; Rangasamy V; Das S; Viswakarma N; Kanthasamy A
Genes Cancer; 2013 Sep; 4(9-10):334-41. PubMed ID: 24349631
[TBL] [Abstract][Full Text] [Related]
2. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis.
Xu Z; Maroney AC; Dobrzanski P; Kukekov NV; Greene LA
Mol Cell Biol; 2001 Jul; 21(14):4713-24. PubMed ID: 11416147
[TBL] [Abstract][Full Text] [Related]
3. Mixed - Lineage Protein kinases (MLKs) in inflammation, metabolism, and other disease states.
Craige SM; Reif MM; Kant S
Biochim Biophys Acta; 2016 Sep; 1862(9):1581-6. PubMed ID: 27259981
[TBL] [Abstract][Full Text] [Related]
4. Mixed-lineage kinase control of JNK and p38 MAPK pathways.
Gallo KA; Johnson GL
Nat Rev Mol Cell Biol; 2002 Sep; 3(9):663-72. PubMed ID: 12209126
[TBL] [Abstract][Full Text] [Related]
5. MST/MLK2, a member of the mixed lineage kinase family, directly phosphorylates and activates SEK1, an activator of c-Jun N-terminal kinase/stress-activated protein kinase.
Hirai Si; Katoh M; Terada M; Kyriakis JM; Zon LI; Rana A; Avruch J; Ohno S
J Biol Chem; 1997 Jun; 272(24):15167-73. PubMed ID: 9182538
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of mixed lineage kinases in dendritic cells.
Handley ME; Rasaiyaah J; Barnett J; Thakker M; Pollara G; Katz DR; Chain BM
Int Immunol; 2007 Aug; 19(8):923-33. PubMed ID: 17698565
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells.
Mathiasen JR; McKenna BA; Saporito MS; Ghadge GD; Roos RP; Holskin BP; Wu ZL; Trusko SP; Connors TC; Maroney AC; Thomas BA; Thomas JC; Bozyczko-Coyne D
Brain Res; 2004 Apr; 1003(1-2):86-97. PubMed ID: 15019567
[TBL] [Abstract][Full Text] [Related]
8. Mixed lineage kinases (MLKs): a role in dendritic cells, inflammation and immunity?
Handley ME; Rasaiyaah J; Chain BM; Katz DR
Int J Exp Pathol; 2007 Apr; 88(2):111-26. PubMed ID: 17408454
[TBL] [Abstract][Full Text] [Related]
9. Mixed lineage kinase LZK forms a functional signaling complex with JIP-1, a scaffold protein of the c-Jun NH(2)-terminal kinase pathway.
Ikeda A; Hasegawa K; Masaki M; Moriguchi T; Nishida E; Kozutsumi Y; Oka S; Kawasaki T
J Biochem; 2001 Dec; 130(6):773-81. PubMed ID: 11726277
[TBL] [Abstract][Full Text] [Related]
10. Mixed lineage kinase-4 promotes gastric carcinoma tumorigenesis through suppression of the c-Jun N-terminal kinase signaling pathway.
Xi Y; Niu J; Li D; He J; Qin L; Peng X
Exp Ther Med; 2018 Oct; 16(4):3317-3324. PubMed ID: 30233678
[TBL] [Abstract][Full Text] [Related]
11. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family.
Teramoto H; Coso OA; Miyata H; Igishi T; Miki T; Gutkind JS
J Biol Chem; 1996 Nov; 271(44):27225-8. PubMed ID: 8910292
[TBL] [Abstract][Full Text] [Related]
12. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease.
Silva RM; Kuan CY; Rakic P; Burke RE
Mov Disord; 2005 Jun; 20(6):653-64. PubMed ID: 15719422
[TBL] [Abstract][Full Text] [Related]
13. MLK4β functions as a negative regulator of MAPK signaling and cell invasion.
Abi Saab WF; Brown MS; Chadee DN
Oncogenesis; 2012 Mar; 1(3):e6. PubMed ID: 23552557
[TBL] [Abstract][Full Text] [Related]
14. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6.
Tibbles LA; Ing YL; Kiefer F; Chan J; Iscove N; Woodgett JR; Lassam NJ
EMBO J; 1996 Dec; 15(24):7026-35. PubMed ID: 9003778
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors.
Shen YH; Godlewski J; Zhu J; Sathyanarayana P; Leaner V; Birrer MJ; Rana A; Tzivion G
J Biol Chem; 2003 Jul; 278(29):26715-21. PubMed ID: 12738796
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation.
Gallo KA; Ellsworth E; Stoub H; Conrad SE
Pharmacol Ther; 2020 Mar; 207():107457. PubMed ID: 31863814
[TBL] [Abstract][Full Text] [Related]
17. Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3.
Leung IW; Lassam N
J Biol Chem; 1998 Dec; 273(49):32408-15. PubMed ID: 9829970
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells.
Cha H; Dangi S; Machamer CE; Shapiro P
Cell Signal; 2006 Jan; 18(1):93-104. PubMed ID: 15923109
[TBL] [Abstract][Full Text] [Related]
19. Domain specificity of MAP3K family members, MLK and Tak1, for JNK signaling in Drosophila.
Stronach B; Lennox AL; Garlena RA
Genetics; 2014 Jun; 197(2):497-513. PubMed ID: 24429281
[TBL] [Abstract][Full Text] [Related]
20. POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis.
Xu Z; Kukekov NV; Greene LA
EMBO J; 2003 Jan; 22(2):252-61. PubMed ID: 12514131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
